Murat Karamese
Atatürk University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Murat Karamese.
Asian Pacific Journal of Cancer Prevention | 2015
Murat Karamese; Sabiha Aydogdu; Selina Aksak Karamese; Ulku Altoparlak; Cemal Gundogdu
BACKGROUND Hepatitis B virus infection is one of the major world health problems. Epigallocatechin-3 gallate is the major component of the polyphenolic fraction of green tea and it has an anti-viral, anti-mutagenic, anti- tumorigenic, anti-angiogenic, anti-proliferative, and/or pro-apoptotic effects on mammalian cells. In this study, our aim was to investigate the inhibition of HBV replication by epigallocatechin-3 gallate in the Hep3B2.1-7 hepatocellular carcinoma cell line. MATERIALS AND METHODS HBV-replicating Hep3B2.1-7 cells were used to investigate the preventive effects of epigallocatechin-3 gallate on HBV DNA replication. The expression levels of HBsAg and HBeAg were determined using ELISA. Quantitative real-time-PCR was applied for the determination of the expression level of HBV DNA. RESULTS Cytotoxicity of epigallocathechin-3-gallate was not observed in the hepatic carcinoma cell line when the dose was lower than 100 μM. The ELISA method demonstrated that epigallocatechin-3 gallate have strong effects on HBsAg and HBeAg levels. Also it was detected by real-time PCR that epigallocatechin-3 gallate could prevent HBV DNA replication. CONCLUSIONS The obtained data pointed out that although the exact mechanism of HBV DNA replication and related diseases remains unclear, epigallocatechin-3 gallate has a potential as an effective anti-HBV agent with low toxicity.
The Eurasian Journal of Medicine | 2017
Osman Ondas; Orhan Ates; Sadullah Keles; Kenan Yildirim; Orhan Baykal; Selina Aksak Karamese; Murat Karamese; Hakan Uslu; Mustafa Yıldırım; Muhammet Emin Naldan; Irem Ates
Objective The purpose of this study was to compare the use of an intravitreal injection of infliximab and of dexamethasone combined with vancomycin to treat experimental endophthalmitis induced by Staphylococcus epidermidis. Materials and Methods The study was conducted between March 25 and April 13, 2012. Twenty-five six-month-old healthy rabbits were used, each weighing 2.5-3 kg. The rabbits were randomized into five groups with five animals per group. Endophthalmitis was induced by 0.1 mL (103 colony-forming units) S. epidermidis in all groups. In group 1, injection was not implemented after the occurrence of endophthalmitis. In groups 2, 3, and 4, the following intravitreal injections were given 24 h after the occurrence of endophthalmitis: group 2, 0.1 mg/0.1 mL vancomycin; group 3, 1 mg/0.1 mL vancomycin and 1 mg/0.1 mL dexamethasone; and group 4, 1 mg/0.1 mL vancomycin and 2 mg/0.1 mL infliximab. Group 5 was the control/uninfected group. The rabbits were clinically assessed each day for seven days. On day 9, a histopathologic evaluation was performed after enucleation. Results After a clinical evaluation, no statistically significant difference was found between the vancomycin+infliximab and vancomycin+dexamethasone groups (p>0.05). The difference was significant when both groups were compared with the vancomycin group (p<0.001). After the histopathologic evaluation, no statistically significant difference was found among the three groups (p>0.05). Conclusion An intravitreal injection of infliximab and of dexamethasone combined with vancomycin have similar clinical and histopathologic effects. To supplement the antibiotic treatment of endophthalmitis, infliximab in a safe dose range can be used as an alternative to dexamethasone to suppress inflammation and prevent ocular damage.
International Journal of Developmental Neuroscience | 2015
Murat Karamese; Selina Aksak Karamese; Emre Karakus; Ozge Beyza Gundogdu; Bunyami Unal
This article has been removed: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our‐business/policies/article‐withdrawal)This article has been removed: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal) This meeting abstract has been removed by the Publisher. Due to an administrative error, abstracts that were not presented at the ISDN 2014 meeting were inadvertently published in the meetings abstract supplement. The Publisher apologizes to the authors and readers for this error.
International Journal of Ophthalmology | 2013
Özgür Çakıcı; Selina Aksak; Deniz Unal; Sare Sipal; Sadullah Keles; Talha Dumlu; Murat Karamese
AIM To determine the histopathological changes of rifampicin applied intravitreally on retinal ganglion cells by means of stereological and histopathological methods. METHODS For this study twenty-four New Zealand adult rabbits were divided into four groups (n=6 for each group). 50µg/0.1mL (group 1), 100µg/0.1mL (group 2), 150µg/0.1mL (group 3) and 200µg/0.1mL (group 4), rifampicin were injected into the vitreous of the right eyes of animals, their left eyes were used as control (group 5). After the 28(th) day of application, animals were anesthetised with xylazine (8mg/kg, IM) and then their eyes were enucleated immediately. Patterns were taken away and eyes were prepared for both stereological and electromicroscopic observation. RESULTS Depending on the high dose of rifampicin, some histopathological changes such as cytoplasmic dilatation and damaged membrane were observed on the electromicroscopic level. Using quantitative examination, which was done at the light microscopic level, it was shown that the number of neurons decreased linearly as rifampicin dose increased when compared with the control group. CONCLUSION Based on these findings, low-dose rifampicin (50µg/0.1mL) may be useful for treatment of the ocular diseases.
Kafkas Journal of Medical Sciences | 2016
Cigdem Eda Balkan; Murat Karamese; Demet Çelebi; Sabiha Aydogdu; Yalçın Dicle; Zeki Calik
Iranian Journal of Basic Medical Sciences | 2016
Murat Karamese; Bulent Guvendi; Selina Aksak Karamese; Irfan Cinar; Serpil Can; Hüseyin Serkan Erol; Hakan Aydin; Volkan Gelen; Emre Karakus
SOJ Microbiology & Infectious Diseases | 2014
Sabiha Aydogdu; Murat Karamese; Ulku Altoparlak
Medical Hypotheses | 2013
Murat Karamese; Selina Aksak; Ozge Beyza Gundogdu; Bunyami Unal
Bezmialem Science | 2018
Sabiha Aydogdu; Ataturk Universitesi Tip Fakultesi, Tibbi Mikrobiyoloji Anabilim Dali, Erzurum, Turkiye; Murat Karamese; Ulku Altoparlak; Selina Aksak Karamese; Kafkas Universitesi Tip Fakultesi, Tibbi Mikrobiyoloji Anabilim Dali, Kars, Turkiye
Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi / Mugla Medical Journal | 2016
Ahmet Berhan Yilmaz; Murat Karamese; Önder Akkaş; Hakan Uslu